Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple MyelomaFrancesco Maura, Kenneth H. Shain, Meghan Menges et al.|Blood|2024Cited by 9
Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaFrancesco Maura, Kenneth H. Shain, Ciara L. Freeman et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 2
De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and ImmunosuppressionMark B. Meads, Kenneth H. Shain, Xiaohong Zhao et al.|Blood|2024Cited by 1